Medical Marijuana for Epilepsy and Seizure Disorders in Ohio

Epilepsy and seizure disorders represent one of the most research-supported areas of medical cannabis use — and one of the qualifying conditions with the clearest FDA-level validation. For Ohio patients managing epilepsy or another seizure disorder, particularly those whose seizures have not responded adequately to standard antiepileptic medications, Ohio’s medical marijuana program provides a physician-supervised legal pathway worth understanding in full.

Does Epilepsy Qualify for Medical Marijuana in Ohio?

Yes. Epilepsy and other seizure disorders are explicitly listed as qualifying conditions under Ohio Revised Code Section 3796.01. Ohio law covers epilepsy and seizure disorders broadly — not just specific epilepsy syndromes — meaning patients with a range of diagnosed seizure conditions may qualify.

A physician holding a Certificate to Recommend (CTR) issued by the State Medical Board of Ohio evaluates whether your documented diagnosis and seizure history support a medical marijuana recommendation.

What Types of Seizure Disorders Qualify in Ohio?

Ohio’s qualifying language covers epilepsy and other seizure disorders broadly. This includes but is not limited to:

• Epilepsy — including focal epilepsy, generalized epilepsy, and combined generalized and focal epilepsy
• Lennox-Gastaut syndrome
• Dravet syndrome
• Treatment-resistant epilepsy — where standard antiepileptic medications have not achieved adequate seizure control
• Other diagnosed seizure disorders where a physician determines medical marijuana is appropriate

The critical context here is treatment resistance. Approximately one third of epilepsy patients have seizures that do not respond adequately to standard antiepileptic medications — a group often referred to as having treatment-resistant or refractory epilepsy. This population is the most frequently discussed in medical cannabis research and represents a significant portion of Ohio epilepsy patients considering the program.

What Does the Research Show About Cannabinoids and Epilepsy?

Epilepsy is one of the conditions with the strongest and most specific evidence base for a cannabinoid-based treatment — but the picture requires careful framing because CBD and THC have very different evidence profiles in this area.

Why CBD Is the Primary Focus for Epilepsy?

Unlike most conditions where THC plays a significant or equal role, epilepsy research has focused primarily on CBD rather than THC. As reviewed in research published through PMC, while early studies explored smoked cannabis for seizure control, the psychoactive effects of THC limited its applicability — and research attention shifted to CBD’s anticonvulsant properties. CBD’s non-intoxicating profile and interaction with multiple neurological pathways made it a more viable candidate for seizure management research.

The FDA Validation — Epidiolex

The most significant development in cannabinoid treatment for epilepsy is the FDA approval of Epidiolex — a pharmaceutical-grade CBD product — for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. This FDA approval represents the first cannabis-derived medication approved in the United States and reflects the clinical trial evidence supporting CBD’s anticonvulsant effects in specific epilepsy syndromes.

What Clinical Research Shows

A systematic review published through PubMed examining evidence for cannabis and cannabinoids in epilepsy across 36 studies — including 6 randomized controlled trials and 30 observational studies — found that CBD at 20 mg/kg/day was more effective than placebo at reducing seizure frequency by 50% or more, with a number needed to treat of 8. Across 17 observational studies, 48.5% of patients reported 50% or more reductions in seizures, and 8.5% were seizure-free.

A literature review published through PMC examining trials from 1978 onward concluded that CBD is considered safer and more effective than THC in treating seizures, with less adverse psychotropic effects.

What the Research Does Not Yet Fully Establish

In reviewing the full picture, honest assessment requires noting that results are not uniform. An observational study published through PubMed following 29 patients with treatment-resistant epilepsies treated with high-CBD/low-THC formulations for 24 weeks or more found no significant differences in convulsive seizure frequency, seizure duration, or rescue medication use compared to baseline — concluding that the doses of CBD used were lower than prior studies and that larger randomized trials are needed.

A focused review published through PMC noted that while CBD has demonstrated efficacy in specific rare epilepsy syndromes, evidence for its broader application across all seizure types is still developing.

The most consistent finding across the research is that pharmaceutical-grade CBD shows meaningful benefit for specific treatment-resistant epilepsy syndromes — particularly Dravet syndrome and Lennox-Gastaut syndrome — while evidence across broader seizure disorder categories continues to develop.

Important Considerations for Epilepsy Patients Using Medical Marijuana?

Drug Interactions With Antiepileptic Medications

This is one of the most clinically important considerations for Ohio epilepsy patients and one that most sites overlook entirely. Cannabinoids — particularly CBD — can interact significantly with antiepileptic medications metabolized through the cytochrome P450 enzyme system.

CBD has been documented to increase blood levels of clobazam and its active metabolite, which can increase the medication’s effectiveness but also its side effects. Similar interactions have been documented with valproate and other common antiseizure drugs. This is not a reason to avoid medical marijuana — it is a reason to ensure your evaluating physician is fully informed of all antiepileptic medications you take, and that your neurologist or epileptologist is involved in the decision.

THC and Seizure Risk

While CBD has the clearest anticonvulsant evidence, THC’s relationship with seizures is more complex. As noted in research published through PubMed, there is limited evidence to suggest that cannabinoids may also induce seizures in some contexts. Ohio epilepsy patients are generally advised to discuss with their physician whether CBD-dominant or high-CBD products are more appropriate for their specific situation than THC-containing products.

What Documentation Do Ohio Epilepsy Patients Need for Their Evaluation?

Ohio-certified physicians evaluating epilepsy and seizure disorder patients look for:

Neurologist or physician records confirming your epilepsy or seizure disorder diagnosis — records from a neurologist, epileptologist, or primary care physician documenting your diagnosis. This is the most important document.

Seizure history documentation — records showing seizure frequency, seizure type, and how your condition has progressed over time.

Antiepileptic medication history — records showing which medications you have tried and their outcomes. For treatment-resistant epilepsy patients, documentation of failed medication trials is particularly relevant.

Current medication list — essential for the OARRS check and for the physician to assess potential interactions between cannabinoids and your current antiepileptic regimen.

How the Online Evaluation Works for Ohio Epilepsy Patients?

Ohio’s OMMCP allows telemedicine evaluations statewide. Epilepsy and seizure disorder patients complete the entire process online.

Step 1 — Book an appointment. Complete a short intake form and select a time with an Ohio-certified physician. Same-day and next-day appointments are frequently available.

Step 2 — Brief video consultation. A physician holding a Certificate to Recommend reviews your epilepsy diagnosis, seizure history, current medications, and treatment history. Most calls take 10 to 20 minutes. Having your current antiepileptic medication list ready is particularly important for this evaluation.

Step 3 — OARRS check. Ohio law requires physicians to run an Automated Rx Reporting System check to identify potential contraindications — especially important for epilepsy patients given the documented interactions between cannabinoids and antiepileptic medications.

Step 4 — Registry submission. If approved, your physician submits your recommendation directly to the Ohio Patient & Caregiver Registry. You’ll receive a confirmation email.

Step 5 — Card activation. Activate your digital card via the link in your email and show it on your phone at any licensed Ohio dispensary statewide.

If you are an Ohio epilepsy or seizure disorder patient and want to find out whether you qualify for the medical marijuana program, you can schedule an online evaluation with an Ohio-certified provider here.

Frequently Asked Questions

Sources

• Ohio Revised Code Section 3796.01 — Qualifying Medical Conditions — Ohio Laws
• State Medical Board of Ohio — Medical Marijuana Program — med.ohio.gov
• Ohio Patient & Caregiver Registry — Ohio Division of Cannabis Control
• Evidence for Cannabis and Cannabinoids for Epilepsy: A Systematic Review — PubMed
• Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? — PMC / NIH
• Cannabidiol in the Treatment of Epilepsy: A Focused Review — PMC / NIH
• Epilepsy and Cannabis: A Literature Review — PMC / NIH
• Observational Study of Medical Marijuana for Treatment-Resistant Epilepsies — PubMed
• Cannabis Use Disorder and Epilepsy — PubMed